NASDAQ:TNYA

Tenaya Therapeutics Q3 2026 Earnings Results & Report

Tenaya Therapeutics logo
$0.29 -0.01 (-3.85%)
As of 03:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tenaya Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.08 versus the -$0.1033 consensus estimate, while revenue of $1.70 million topped the $800 thousand estimate by $897 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Tenaya Therapeutics EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.1033
Beat/Miss
Beat by +$0.0233
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Tenaya Therapeutics Revenue Results

Actual Revenue
$1.70 million
Expected Revenue
$800 thousand
Beat/Miss
Beat by +$897.00 thousand
YoY Revenue Growth
N/A

Tenaya Therapeutics Q3 2026 Earnings FAQ

Tenaya Therapeutics (NASDAQ:TNYA) reported earnings of -$0.08 per share for Q3 2026, beating the consensus estimate of -$0.1033. The report was announced on Wednesday, November 4, 2026.

Tenaya Therapeutics reported revenue of $1.70 million for Q3 2026, against a consensus estimate of $800 thousand.

Tenaya Therapeutics Earnings Headlines

FY2026 Earnings Forecast for TNYA Issued By HC Wainwright
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Tenaya Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email.

About Tenaya Therapeutics

Tenaya Therapeutics (NASDAQ:TNYA) is a clinical-stage biotechnology company focused on developing treatments for heart disease. Based in South San Francisco, California, the company uses genetic medicine and other therapeutic approaches to target the underlying causes of cardiac conditions.

Its investigational programs include TN-201, a gene therapy candidate for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Tenaya has also developed TN-301, an oral small-molecule candidate studied for heart failure with preserved ejection fraction.

Tenaya’s candidates are investigational and are not approved medicines. The company was founded in 2016 and focuses its research and development on therapies for serious heart diseases.

View Tenaya Therapeutics Profile